VisionGate Adds Three Prominent Directors to its Board

Home
News
VisionGate Adds Three Prominent Directors to its Board

VisionGate Adds 3 Prominent Directors

VisionGateAI Awarded Prestigious Andy Hill CARE Fund Grant to Advance Early-Stage Lung Cancer Detection

October 6, 2026|0 Comments

WCLC 2025 – AI subclassification of abnormal cells into pre-cancerous and malignant categories based on 3D cell imaging

October 24, 2025|0 Comments

Home
About
Our Technology

Contact

3 Questions to Assess Your Risk

Early detection of lung cancer is important to keeping you healthy and living your life to the fullest.

We'll start by identifying your age: *

Has a family member had Lung Cancer? *

Yes

No

Have you smoked or been exposed to secondhand smoke? *

Yes

No

If you are over the age of 60 or answer "Yes" to any of the questions above, you may be at an increased risk.

This test is not a diagnosis but can help you recognize factors that may increase your risk of developing lung cancer. Next, You can subscribe to learn more from VisionGate. Then, you'll be redirected to a page of resources that can aid you in discussions with your doctor, or click here to access the page directly.

Enter Your Name *

Enter Your Email *

Yes, I would like to receive updates from VisionGate*

If you are above the age of 50 and answered "Yes" to any of the questions, you may be at an increased risk of developing lung cancer, but this is not a diagnosis. Use the link below to download resources that can help you talk to your doctor. Click Here to Download

We're sorry! There was an error submitting the test. Please try again later.

*No personal information is collected or saved through this form without your consent. Only your email and name will be saved if you opt-in.

Contact

Home
About
Our Technology

Page load link

Go to Top

VisionGate Adds Three Prominent Directors to its Board

Related Posts

VisionGateAI Awarded Prestigious Andy Hill CARE Fund Grant to Advance Early-Stage Lung Cancer Detection

WCLC 2025 – AI subclassification of abnormal cells into pre-cancerous and malignant categories based on 3D cell imaging